142 related articles for article (PubMed ID: 21054138)
1. Finding drugs against CD133+ glioma subpopulations.
Nakano I; Chiocca EA
J Neurosurg; 2011 Mar; 114(3):648; discussion 648-50. PubMed ID: 21054138
[No Abstract] [Full Text] [Related]
2. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.
Fang KM; Lin TC; Chan TC; Ma SZ; Tzou BC; Chang WR; Liu JJ; Chiou SH; Yang CS; Tzeng SF
Glia; 2013 Sep; 61(9):1402-17. PubMed ID: 23832679
[TBL] [Abstract][Full Text] [Related]
4. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells.
Yang MY; Lee HT; Chen CM; Shen CC; Ma HI
Int J Mol Sci; 2014 Jun; 15(6):11013-29. PubMed ID: 24945311
[TBL] [Abstract][Full Text] [Related]
6. Limits of CD133 as a marker of glioma self-renewing cells.
Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I
Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
[TBL] [Abstract][Full Text] [Related]
8. Targeting brain-tumor stem cells.
Stupp R; Hegi ME
Nat Biotechnol; 2007 Feb; 25(2):193-4. PubMed ID: 17287755
[No Abstract] [Full Text] [Related]
9. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Lönnroth C; Andersson M; Nordgren S; Lundholm K
Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
[TBL] [Abstract][Full Text] [Related]
10. The pathological characteristics of glioma stem cell niches.
He H; Li MW; Niu CS
J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
Song WC; Fei XF; Dong J
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
[TBL] [Abstract][Full Text] [Related]
12. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells.
Lehnus KS; Donovan LK; Huang X; Zhao N; Warr TJ; Pilkington GJ; An Q
Int J Oncol; 2013 Mar; 42(3):1011-7. PubMed ID: 23340741
[TBL] [Abstract][Full Text] [Related]
13. [Chemoresistance of CD133(+) tumor stem cells from human brain glioma].
Bi CL; Fang JS; Chen FH; Wang YJ; Wu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):568-73. PubMed ID: 17767043
[TBL] [Abstract][Full Text] [Related]
14. Cancer: stem cells and brain tumours.
Dirks PB
Nature; 2006 Dec; 444(7120):687-8. PubMed ID: 17151644
[No Abstract] [Full Text] [Related]
15. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A
Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792
[TBL] [Abstract][Full Text] [Related]
16. CD133 is a marker of bioenergetic stress in human glioma.
Griguer CE; Oliva CR; Gobin E; Marcorelles P; Benos DJ; Lancaster JR; Gillespie GY
PLoS One; 2008; 3(11):e3655. PubMed ID: 18985161
[TBL] [Abstract][Full Text] [Related]
17. Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells.
Yu SP; Yang XJ; Zhang B; Ming HL; Chen C; Ren BC; Liu ZF; Liu B
Chin Med J (Engl); 2011 Sep; 124(17):2599-604. PubMed ID: 22040410
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CD133 promotes drug resistance in C6 glioma cells.
Angelastro JM; Lamé MW
Mol Cancer Res; 2010 Aug; 8(8):1105-15. PubMed ID: 20663862
[TBL] [Abstract][Full Text] [Related]
19. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
20. Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells.
Niu CS; Li DX; Liu YH; Fu XM; Tang SF; Li J
Oncol Rep; 2011 Sep; 26(3):593-601. PubMed ID: 21573506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
